<DOC>
	<DOCNO>NCT00773149</DOCNO>
	<brief_summary>Alemtuzumab anti CD52 monoclonal antibody . The CD52 antigen present surface B , T NK lymphocytes . It express various level surface ALL blast cell . Adult patient ALL relapse less 10 % probability long term survival . The present study test response rate ( partial complete remission ) refractory ALL ALL relapse . It hop CR achieve , consideration give hematopoietic stem cell transplant . The use G-CSF justify possible increase ADCC .</brief_summary>
	<brief_title>Alemtuzumab ( CAMPATH 1H ) Associated G-CSF Adult Patients With Refractory Acute Lymphocytic Leukemia</brief_title>
	<detailed_description>All patient receive Alemtuzumab 3 successive phase : Phase A : Test week : 3mg , 10mg , 30mg every day one week test tolerance . Phase B : 30mg 3 time week 12 18 administration response progression/failure document . Phase C : patient CR , maintenance Alemtuzumab : 3 injection one week every 2 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Patients older 15 year Refractory ALL ALL relapse post chemotherapy post transplant ALL blast cell express CD 52 antigen time evolution disease . Signed informed consent Patients social security coverage Anti conceptional tablet pre menopausal woman . Children 15 year age age 15 Blast cell express CD52 antigen ( evaluation ) HIV positivity ECOG Score 3 4 Hypersensitivity Alemtuzumab . Pregnancy breast feeding . Other malignant disease addition ALL .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Adult Acute Lymphocytic Leukemia</keyword>
	<keyword>Alemtuzumab</keyword>
</DOC>